Blog

Anxiety and depression in Myeloproliferative Neoplasm patients

Nationwide Population-based survey in Denmark Objective: We sought to determine the prevalence and severity of anxiety and depression among patients with Philadelphia-negative myeloproliferative neoplasms (MPNs) and respective associations of anxiety and depression with demographic and lifestyle factors, comorbidity burden, duration of MPN disease, financial difficulties, and health-related quality of life (QoL). Methods: This study used […]

Benefit of Ruxolitinib Treatment in Polycythemia Vera by Dr. Verstovsek

Dr. Verstovsek on Benefit of Ruxolitinib Treatment in PV Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the benefit of ruxolitinib (Jakafi) in the treatment of patients with polycythemia vera (PV). Not only has the JAK inhibitor […]

MPN Cancer Connection partners with PAN Foundation on Medication Assistance Programs for MPN Patients

by David Wallace MPN Cancer Connection is very pleased to announce a new partnership with the PAN Foundation. Myeloproliferative Neoplasm (MPN) patients may be eligible for $8,500 per year (or more if a 2nd grant is needed/approved) in assistance assuming you meet the eligibility criteria which are very reasonable. The status is presently […]

Risk of Myeloid Blood Cancers are increased in relatives of patients

The largest ever study of its type is the first to definitively show an increased risk of blood cancers in relatives of patients. A team led by scientists at The Institute of Cancer Research, London, and the German Cancer Research Centre in Heidelberg have uncovered new evidence, supporting a role for inherited genetic changes influencing the […]

Nathalie-Cook-holding-Pegasys-for-MPN-patients

MPN Patient Advocacy Works

Inspiring, tenacious and rewarding work that will benefit the lives of so many. Australian MPN patients can now have affordable access to Pegasys. This is the kind of success I would like to see happen around the globe. It takes a lot of time, effort, and dedication. Bravo Nathalie, I’m so proud of you and the […]

ASH Partners with UNC, a ClinGen grantee to Curate Genomic data for Blood Research

Publisher’s Note: My source at the American Society of Hematology (ASH) informed me that “initially MPNs aren’t going to be a primary focus, however, we expect that this project will lead to better understanding of MPNs in the future.” Thanks to the American Society of Hematology for being the source for this article. While this […]

Ruxolitinib Metformin combo: A Possible Alternative Treatment for Myeloproliferative Neoplasm Patients

Metformin demonstrates antileukemic activity and may have clinical implications for the treatment of myeloproliferative neoplasms (MPN) in combination with ruxolitinib, according to a study published in Cell Death & Disease. The JAK1/2 inhibitor ruxolitinib demonstrates clinical activity among patients with MPN (eg, essential thrombocythemia, primary myelofibrosis, polycythemia vera), but rarely produces a complete response. Data from previous studies […]

How MPN Blood Cancers outsmart the Immune System

AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE Researchers have discovered how some of the blood cancers known as myeloproliferative neoplasms (MPNs) evade the immune system. Their findings reveal that a subset of MPNs might be susceptible to treatment with immune checkpoint inhibitors that specifically target the PD-1/PD-L1 pathway (a signaling network that normally functions as […]

Imago BioSciences gets FDA Approval of IND Application for Treatment of Myelofibrosis, IMG-7289 in Clinical Trials

Imago BioSciences, a clinical-stage pharmaceutical company developing novel therapies for hematological and inflammatory diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted their Investigational New Drug (IND) application providing clearance to proceed with the clinical development of IMG-7289 in the U.S. The IND supports the company’s ongoing Phase 1/2 clinical trial of […]

Celgene Acquires Impact Biomedicines, Adding Myeloproliferative Neoplasm Drug Fedratinib to Its Pipeline

Celgene Corporation (NASDAQ:CELG) and Impact Biomedicines today announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines, which is developing fedratinib for myelofibrosis and polycythemia vera. Under the terms of the agreement, Celgene will pay approximately $1.1 billion upfront and up to $1.25 billion in contingent payments based on regulatory approval […]